| Ytd | 129.76% | |
| 1y | 101.04% |
| Open | 1.72 | Prev Close | 1.67 | Low | 1.65 | High | 1.97 | Mkt Cap | 87.10M |
| Vol | 3.27M | Avg Vol | 357.87K | EPS | -0.31 | P/E | N/A | Forward P/E | -3.10 |
| Beta | 0.99 | Short Ratio | 3.43 | Inst. Own | 8.18% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 1.05 | 200-d Avg | 0.96 | 1yr Est | 5.50 |
RNXT News
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the
Gainers Picard Medical (AMEX:PMI) shares moved upwards by 82.7% to $9.38 during Tuesday's regul
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company
PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial The Study Shows Approximat
MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company
As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectua
RenovoRx NASDAQ: RNXT executives and physician speakers discussed the treatment landscape for locall
RenovoRx NASDAQ: RNXT reported record second-quarter revenue as it expanded its commercial cancer-ce
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus E
Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market
RenovoRx (NASDAQ:RNXT) raises FY2026 sales outlook from $3.000 million-$4.000 million to $3.750 mill
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.05) per share which beat the analyst consens
Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered wit
MOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”
RenovoRx finishes Phase 3 TIGeR-PaC trial enrollment for locally advanced pancreatic cancer, expecti
Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's af
MOUNTAIN VIEW, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”
MOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”
MOUNTAIN VIEW, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”
RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026
MOUNTAIN VIEW, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
MOUNTAIN VIEW, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”
Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price tar
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the
The designation was issued by the FDA's Office of Orphan Products Development pursuant to Sectio
Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and
Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial
Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial
MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”)
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Conse
RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.000 million-$4.000 million to $3.000 mil
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensu
Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer
RenovoRx (RNXT) doesn't possess the right combination of the two key ingredients for a likely earnin
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates RenovoRx (NASDAQ:RNXT) with a B
The allowed claims of the patent protect the RenovoCath dual-occlusion catheter-based system equippe
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensu
The proceeds from this financing are expected to allow RenovoRx to capitalize on and accelerate its
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the
RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company